IP Library Granted Patent US 11,136,599
Granted Patent B2
US 11,136,599 · App. 16/838,804 · Granted Oct 5, 2021

Artifical nucleases comprising engineered cleavage half-domains

Inventors: Yannick Doyon (Quebec City, CA); Jeffrey C. Miller (Richmond, CA)
Assignee: Sangamo Therapeutics, Inc.
C12N15/907C07K7/06C07K14/47C12N9/22C12N15/85C07K2319/50C07K2319/80C07K2319/81C12Y301/21004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,136,599
App. No.
16/838,804
Granted
Oct 5, 2021
Kind
B2
Abstract

Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.

Claims (25)

1. An artificial nuclease comprising:

(i) a DNA-binding domain that binds to a target site in the genome of the cell; and

(ii) a polypeptide comprising an engineered FokI cleavage half-domain consisting of substitution mutations numbered relative to a wild-type FokI sequence as shown in SEQ ID NO:57, wherein the substitution mutations are as follows:

the wild-type isoleucine (I) residue at position 499 is replaced with a threonine residue (T) (I499T);

the wild-type 1 residue at position 538 is replaced with a phenylalanine (F) residue (I538F);

the wild-type 1 residue at position 538 is replaced with a T residue (I538T); the wild-type Q residue at position 486 is replaced with a L residue and the wild-type lysine (K) residue at position 448 is replaced with a methionine (M) residue (Q486L:K448M);

the wild-type asparagine (N) residue at position 496 is replaced with an aspartic acid (D) residue and the wild-type glutamic acid (E) residue at position 484 is replaced with a valine (V) residue (N496D:E484V);

the wild-type histidine residue at position 537 is replaced with a L residue, the wild-type alanine (A) residue a position 482 is replaced with a T residue, the wild-type lysine (K) residue at position 559 is replaced with a T residue and the L residue at position 563 is replaced with an M residue (H537L:A482T:K559T:L563M);

the wild-type Q residue at position 531 is replaced with an arginine (R) residue (Q531R);

the wild-type Q residue at position 531 is replaced with a R residue and the wild-type V residue at position 512 is replaced with a M residue (Q531R:V512M);

the wild-type N residue at position 500 is replaced with a serine (S) residue, the wild-type K residue at position 402 is replaced with an R residue, the wild-type K residue at position 427 is replaced with an M residue and the wild-type N residue at position 578 is replaced with a S residue (N500S:K402R:K427M:N578S);

the wild-type N residue at position 500 is replaced with a S residue and the wild-type K residue at position 469 is replaced with an M residue (N500S:K469M);

the wild-type N residue at position 476 is replaced with a D residue (N476D) or a K residue (N476K);

the wild-type glycine (G) residue a position 474 is replaced with a S residue (G474 S);

the wild-type G residue at position 474 is replaced with an A residue (G474A); or

the wild-type D residue at position 467 is replaced with an E residue (D467E).

2. The artificial nuclease of claim 1 , further comprising an additional amino acid substitution at one or more of positions 418, 432, 441, 481, 483, 486, 487, 490, 496, 499, 523, 527, 537, 538 and 559, numbered relative to a wild-type FokI sequence as shown in SEQ ID NO:57.

3. An isolated cell or cell line comprising cells comprising the artificial nuclease of claim 1 .

4. The isolated cell or cell line of claim 3 , wherein the cells comprise a genomic modification.

5. The isolated cell or cell line of claim 4 , wherein the genomic modification comprises a deletion.

6. The isolated cell or cell line of claim 4 , wherein the genomic modification comprises an insertion.

7. The isolated cell or cell line of claim 6 , wherein a donor molecule comprising a sequence encoding a polypeptide is inserted into the genome.

8. The isolated cell or cell line of claim 7 , wherein a donor molecule comprising a sequence encoding an RNA is inserted into the genome.

9. A method of making an isolated cell comprising a genomic modification, the method comprising

simultaneously cleaving the genome of the cell using first and second artificial nucleases according to claim 1 such that the cleaved genome is genetically modified.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2022
From: DOYON, YANNICK; MILLER, JEFFREY C.
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 061816/0800 →
CHANGE OF NAME Recorded Nov 17, 2022
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 061963/0933 →
Continuity (8)
Continuation 16055525 · Aug 6, 2018
Continuation 15660072 · Jul 26, 2017
Continuation 15160571 · May 20, 2016
Continuation 14627812 · Feb 20, 2015
Continuation 12931660 · Feb 7, 2011
Provisional Application 61337769 · Feb 8, 2010
Provisional Application 61403916 · Sep 23, 2010
Related Publication 20200231988A1 · Jul 23, 2020